Interview with Ajit Kamath, Chairman & Managing Director, Arch Pharmalabs
Arch Pharmalabs started its operations in 1999 when you bought a plant in Hyderabad with a turnover of 2Mn USD. 12 years later, you have grown to a 300Mn USD…
Address: 541-A, Arch House, Marol Maroshi Road,
Andheri (E), Mumbai – 400 059, India
Tel: 91-22-33089200/33089400
Web: http://www.archpharmalabs.com/index.asp
We are a pharmaceutical company aligned across two business verticals viz. Products and Services. Our Products business comprises manufacture and sale of APIs and Intermediates to innovator and generic pharmaceutical players in both domestic and international markets including the regulated markets. We have evolved our business and have, over the years, extended from manufacturing APIs and Intermediates to add CRAMS to our offerings, which has significant potential for the growth of our business.
Lipid Lowering Agent
Calcium Channel Blocker
Anti Platelet Agent
Anti hypertensive
Anti anginal
Anti Asthmatic
Anti Histamine
Anti Diabetic
Anti Protozoal
Anti fungal
Oncology
Anti emetic
Proton pump inhibitor
Expectorant
Decongestant
Anti Depressant
Anti Convulsant
Psychostimulant
Hypnotic
Anti parkinsonian
Anti Retroviral
Anti gout
Analgesic
We have evolved to include Contract Research and Manufacturing Services as our growing business vertical. We have developed capabilities to provide a wide range of CRAMS starting from route selection / process development / optimization, analytical development, stability studies, safety studies, scale-up to technology transfer / clinical-trial manufacturing to commercial manufacturing to suit US / EU regulatory requirements. We can cost-effectively manage several complex reactions at various scales of operation, ranging from a few grams to several tonnes. For instance, we, using a proprietary bio-catalytic/ enzymatic technology availed by us, have developed innovative route for the manufacturing of key advanced intermediates.
Arch Pharmalabs started its operations in 1999 when you bought a plant in Hyderabad with a turnover of 2Mn USD. 12 years later, you have grown to a 300Mn USD…
Over the course of its 350-year history, Merck KGaA has expanded from its base in Darmstadt, Germany to establish a strong presence in various markets across the globe. Last year,…
Shagun Sharma, Vipul Kumar Gupta, and Helene Sou of Takeda, writing in the December 2024 edition of DIA’s Global Forum magazine, look at how updates to India’s regulatory framework for…
Contributing to the October 2024 edition of DIA’s Global Forum magazine, Stephanie Rosner of DIA and Martin Hodosi and Rosanna Lim of Kearney highlight the discussions from DIA’s multistakeholder Responsible…
Contributing to the September 2024 edition of DIA’s Global Forum magazine, Siva Kumar Buddha of Indegene reviews the challenges of risk communication and minimization in India’s healthcare sector. In…
Poised to overtake Japan and become the world’s fourth-largest economy by 2025 according to the latest International Monetary Fund estimates and now registering heady year-on-year growth rates exceeding eight percent,…
Halewood Laboratories’ Sanchit Chaturvedi discusses the impact of taking on a leadership role in a challenging personal moment; the company’s enduring commitment to innovation and quality; and its planned expansion…
In the words of Founder and Chairman Kaushik Chaturvedi, Halewood Labs’ success since its foundation in the early 1980s can be put down to three key factors: vision and commitment,…
Managing Director Dr Sharvil Patel outlines the objectives behind the rebranding of the Indian pharma company from Zydus Cadila to Zydus Lifesciences, provides insights into the importance of the US…
India faces a significant diabetes burden, with some observers even labelling the country ‘The Diabetes Capital of the World’. Around 101.4 million adults, or 11 percent of the Indian population,…
BeiGene may not be a profitable business quite yet, but the Chinese biotech has two top oncology products and saw its sales soar to USD 2.2 billion in 2023. Having…
Environmental, Social, and Governance (ESG) concerns have grown in global importance in the last few years due to several factors, including increased awareness of and demand for sustainable investing, the…
Siloed healthcare is no match for a malignant, insidious, and pervasive disease like cancer. Over recent decades, countries and regions across the world have discovered that – in the absence…
See our Cookie Privacy Policy Here
